Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SPI 112 是一种选择性的、有效的、竞争性的SHP2 (PTPN11)抑制剂,对SHP2,蛋白酪氨酸磷酸酶 (PTP) 和 PTP1B 的IC50分别为 1 μM,18.3 μM 和 14.5 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 255 | 现货 | ||
10 mg | ¥ 398 | 现货 | ||
25 mg | ¥ 828 | 现货 | ||
50 mg | ¥ 1,490 | 现货 | ||
100 mg | ¥ 2,220 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 373 | 现货 |
产品描述 | SPI-112, the SPI-112 methyl ester analog, can inhibit cellular Shp2 PTP activity. SPI-112 bound to Shp2 by surface plasmon resonance (SPR) and displayed competitive inhibitor kinetics to Shp2. |
靶点活性 | PTP:18.3 μM (IC50), PTP1B:14.5 μM (IC50), SHP2:1 μM (IC50) |
激酶实验 | The activity of c-KIT kinase is determined by following the production of ADP from the kinase reaction through coupling with the pyruvate kinase/lactate dehydrogenase system. In this assay, the oxidation of NADH (thus the decrease at A340 nM) is continuously monitored spectrophotometrically. The reaction mixture (100 μL) contained c-KIT (cKIT residues T544-V976, from ProQinase, 5.4 nM), polyE4Y (1 mg/mL), MgC12 (10 mM), pyruvate kinase (4 units), lactate dehydrogenase (0.7 units), phosphoenol pyruvate (1 mM), and NADH (0.28 mM) in 90 mM Tris buffer containing 0.2 % octyl-glucoside and 1% DMSO, pH 7.5. Test compounds (e.g., DCC-2618) are incubated with c-KIT and other reaction reagents at 22 °C for < 2 min before ATP (200 μM) is added to start the reaction. The absorption at 340 nm is monitored continuously for 0.5 hours at 30 °C on Polarstar Optima plate reader (BMG). The reaction rate is calculated using the 0 to 0.5 h time frame. Percent inhibition is obtained by comparison of reaction rate with that of a control (i.e. with no test compound). |
分子量 | 468.46 |
分子式 | C22H17FN4O5S |
CAS No. | 1051387-90-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (106.73 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1347 mL | 10.6733 mL | 21.3465 mL | 53.3663 mL |
5 mM | 0.4269 mL | 2.1347 mL | 4.2693 mL | 10.6733 mL | |
10 mM | 0.2135 mL | 1.0673 mL | 2.1347 mL | 5.3366 mL | |
20 mM | 0.1067 mL | 0.5337 mL | 1.0673 mL | 2.6683 mL | |
50 mM | 0.0427 mL | 0.2135 mL | 0.4269 mL | 1.0673 mL | |
100 mM | 0.0213 mL | 0.1067 mL | 0.2135 mL | 0.5337 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SPI-112 1051387-90-6 Metabolism Phosphatase SPI 112 SPR inhibit SHP2 Inhibitor SPI112 PTP1B anticancer PTP PTPN11 competitive inhibitor